Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic
Tahne Vongsavath1, Kyaw Min Tun2, Dwaipayan Mukhopadhyay3
1Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, University of Nevada, Las Vegas, Nevada.
Backgrounds And Aims:
This paper seeks to use existing literature to investigate the use of Cystic Fibrosis Transmembrane Conductance (CFTR) modulators and their safety and effects on the liver enzymes of cystic fibrosis (CF) patients with and without related liver disease (CFLD). This review examines the effect of CFTR modulators on liver enzymes as well as their safety profile.
Methods:
A comprehensive literature review across Pubmed/Medline, Embase, CINAHL, Cochrane, and Web of Science, was performed. Six articles pertaining to CFTR modulator use and liver enzyme information were included. Statistical evaluation was completed using random-effect models with a 95% confidence interval (CI), and group mean differences were analyzed with R software. Forest plots were generated for the observed effect, CI, and the weight of each study. The primary outcome was changes to serum levels of alanine transaminase (ALT), aspartate transaminase, total bilirubin, and gamma-glutamyl transferase. Secondary outcomes for this study were changes in serum biomarkers and type of CFTR modulator used. Other outcomes explored include the safety of CFTR modulator use.
Results:
Patients treated with lumacaftor/ivacaftor had a significant decrease in total bilirubin (-0.70 (-1.26, -0.14); P = .033) and gamma-glutamyl transferase (-0.98 (-1.45, -0.51); P = .012). While ALT had a nonsignificant trend (-0.56 (-1.54, 0.41); P = .20), ALT was noted to decrease significantly in CF patients (-0.90 (-1.71, -0.08); P = .037). When pooled there was significant change in ALT in those with and without CFLD (-0.98 (-1.45, -0.51); P = .012). Reported adverse events were low, with a prevalence of 38% (CI: 8.59%-80%).
Conclusion:
CFTR modulators may influence levels of liver enzymes in CF patients without an increased risk of adverse events.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hepatic Drug Clearance: Role of Transporters
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
